Fifteen (15.6%) patients of 97 with malignant glioma developed meningeal gliomatosis during at least 2 years after the initial treatment. The time between the first surgery and diagnosis of meningeal gliomatosis was less than 1 year in 10 cases, 1 to 2 years in 2 and over 2 years in 2. In the younger age group less than 20 years, the incidence of meningeal gliomatosis was higher (46%) than that (12%) in the older group. Despite intrathecal chemotherapy (cytosine arabinoside, bleomycin and methotrexate), all patients died 2 to 24 weeks after the diagnosis of meningeal gliomatosis. Experimental studies suggest that intrathecal ACNU may be promising for the treatment of meningeal gliomatosis.
Download full-text PDF |
Source |
---|
Medicine (Baltimore)
January 2025
Department of Pathology, Deyang Peoples' Hospital, Deyang, Sichuan Province, China.
Rationale: Ependymomas are commonly prevalent intramedullary neoplasms in adults, with hardly any cases of exophytic extramedullary ependymoma being reported. Meningiomas, on the contrary, are one of the most common intradural extramedullary (IDEM) tumors. However, the occurrence of both IDEM tumors simultaneously is extremely rare.
View Article and Find Full Text PDFAnal Biochem
April 2025
Institute of Nuclear Physics, Polish Academy of Sciences, 31-342, Krakow, Poland; Department of Biochemistry and Molecular Biology, Medical University of Lublin, Lublin, Poland. Electronic address:
Brain tumors are among the most dangerous, due to their location in the organ that governs all life processes. Moreover, the high differentiation of these poses a challenge in diagnostics. Therefore, this study focused on the chemical differentiation of glioblastoma G4 (GBM) and two types of meningiomas (atypical - MAtyp and angiomatous - MAng) were done using Fourier Transform InfraRed (FTIR) spectroscopy, combined with statistical, multivariate, machine learning and rate of spectrum changes methods.
View Article and Find Full Text PDFCell Rep
December 2024
Beijing Institute for Brain Research, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 102206, China; Chinese Institute for Brain Research, Beijing, Beijing 102206, China; Changping Laboratory, Beijing 102206, China. Electronic address:
Glioblastoma represents one of the most aggressive cancers, characterized by severely limited therapeutic options. Despite extensive investigations into this brain malignancy, cellular and molecular components governing its immunosuppressive microenvironment remain incompletely understood. Here, we identify a distinct neutrophil subpopulation, termed disease-specific suppressive granulocytes (DSSGs), present in human glioblastoma and lower-grade gliomas.
View Article and Find Full Text PDFJ Neurooncol
February 2025
Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Introduction: Spinal low-grade gliomas (sLGGs) are a group of tumors that arise from glial cells in the spinal cord. Current evidence supporting the use of adjuvant radiotherapy for the management of sLGG is lacking. We hence aimed to compare overall survival rates in patients receiving surgery alone with those receiving surgery with adjuvant radiotherapy.
View Article and Find Full Text PDFClin Radiol
January 2025
School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan; Department of Radiology, Taipei Veterans General Hospital, Taipei, Taiwan. Electronic address:
Aims: Although leptomeningeal dissemination (LMD) is a hallmark of malignant brain tumors, optic pathway glioma (OPG) of various grades can initially present with LMD, which is thenceforth interpreted as an aggressive tumor. In this study, we aimed to evaluate the clinical and imaging findings of pediatric OPG (POPG) patients who presented with initial LMD to ensure a prompt diagnosis and better outcomes.
Materials And Methods: Between 2000 and 2022, 35 pediatric patients with pathologically proven OPG who presented with and without LMD at our institute were retrospectively reviewed.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!